Analytical Data
-
Gene name
IL-2
- Application
-
Alternative Names
TCGF; Lymphokine; T-Cell Growth Factor; Aldesleukin
-
Species
Dog
-
Source
E. coli
-
Tag
N-His
-
Purity
> 97% as determined by SDS-PAGE.
-
Uniprot
Q29416
-
Expression Region
Met1~Thr155
-
Molecular Weight
21kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-2 (IL-2) is a pivotal cytokine in the immune system, primarily produced by T cells, and it plays a crucial role in the proliferation and activation of immune cells, particularly T lymphocytes. The recombinant form of IL-2 has gained significant attention in biomedical research and therapeutic applications due to its potential to enhance immune responses. Originally discovered for its capacity to support T cell growth, IL-2 has been researched extensively for its implications in cancer immunotherapy, autoimmune diseases, and transplant acceptance. The ability to produce IL-2 recombinantly has enabled scientists to explore its effects in a controlled manner, paving the way for the development of novel treatments aimed at boosting anti-tumor immunity or modulating excessive immune responses. Research involving IL-2 recombinant protein has led to a better understanding of its mechanisms, such as promoting T cell differentiation and memory formation, while also identifying optimal dosing strategies and delivery methods to maximize efficacy and minimize adverse effects. Furthermore, recombinant IL-2 has been integral in developing adoptive cell therapies, such as CAR T-cell therapy, where it is used to enhance the survival and functionality of engineered T cells. Overall, the study of IL-2 recombinant protein represents a cornerstone of immunotherapy research, highlighting its versatility and importance in manipulating the immune system for therapeutic benefit.
